Income Statement

CG ONCOLOGY, INC.

CGON
Performance Overview Click any row in the table to add it to this chart
in millions USD
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY
Revenue
- -
Cost of Revenue
- -
Gross Profit
- -
Operating Expenses
194.81 115.81
Research & Development
116.64 82.10
Selling, General & Administrative
73.53 33.70
Other Operating Expenses
- -
Operating Income
-194.81 -115.81
Non-Operating Income
29.78 26.63
Interest Income
29.93 26.62
Interest Expense
- -
Other Non-Op Income / Expense
-0.15 26.63
Income Before Tax
- -
Income Tax Expense
- -
Non-Controlling Interest
- -
Net Income
-161.00 -88.04
Supplemental Per share data, derived & other items — not part of the income statement
in millions USD unless noted
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY
Depreciation & Amortization
- -
EBITDA
-193.37 -115.77
Earnings Per Share (Basic)
-2.08 -1.41
Diluted EPS
-2.08 -1.41
Weighted Average Shares
77.30 62.50
Diluted Weighted Avg Shares
77.30 62.50
Comprehensive Income
- -